Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03444714 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of RiMO-301 With Radiation in Advanced Tumors
A Phase 1 study, sponsored by Coordination Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT03444714 is a Phase 1 study that has completed, run by Coordination Pharmaceuticals. The registered enrollment target is 32 participants.
The verdict
NCT03444714, a Phase 1 study, has completed, sponsored by Coordination Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with radiation in patients with advanced tumors. A single escalation dose of RiMO-301 is intratumorally injected in a 3 + 3 study design to identify the recommended dose and dosing volumes. Condition or Disease: Patient with advanced tumor which is clinically accessible for intratumoral injection Intervention/Treatment: Drug - RiMO-301 Radiation - Radiotherapy Phase: Phase 1
Interventions
- DRUG RiMO-301
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2018-04-10 |
| Est. Completion | 2025-06-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03444714
The ClinicalTrials.gov registry entry for NCT03444714 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Coordination Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RiMO-301 is the first listed.
NCT03444714 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03444714 about?
NCT03444714 is a clinical study titled "Phase I Study of RiMO-301 With Radiation in Advanced Tumors". This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with radiation in patients with advanced tumors. A single escalation dose of RiMO-301 is intratumorally injected in a 3 + 3 study design to identify the recommended dose and dosing volumes. Condition or Disease: Patien...
What is the current status of trial NCT03444714?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2018-04-10. Estimated completion is 2025-06-16.
What interventions are being tested in trial NCT03444714?
The interventions under investigation include: RiMO-301 (DRUG).
Who is sponsoring clinical trial NCT03444714?
This trial is sponsored by Coordination Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.